Evidence map›Paper›PMID 40649939›Full record

ArticleInternational journal of molecular sciences2025

Shedding of GPP130 by PC7 and Furin: Potential Implication in Lung Cancer Progression.

Priyanka Prabhala, Stephanie Duval, Alexandra Evagelidis, Maïlys Le Dévéhat, Vatsal Sachan, Nabil G Seidah

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Priyanka PrabhalaLaboratory of Biochemical Neuroendocrinology, Montreal Clinical Research Institute (IRCM), affiliated to the University of Montreal, Montreal, QC H2W 1R7, Canada.
Stephanie DuvalLaboratory of Biochemical Neuroendocrinology, Montreal Clinical Research Institute (IRCM), affiliated to the University of Montreal, Montreal, QC H2W 1R7, Canada.
Alexandra EvagelidisLaboratory of Biochemical Neuroendocrinology, Montreal Clinical Research Institute (IRCM), affiliated to the University of Montreal, Montreal, QC H2W 1R7, Canada.
Maïlys Le DévéhatLaboratory of Biochemical Neuroendocrinology, Montreal Clinical Research Institute (IRCM), affiliated to the University of Montreal, Montreal, QC H2W 1R7, Canada.
Vatsal SachanLaboratory of Biochemical Neuroendocrinology, Montreal Clinical Research Institute (IRCM), affiliated to the University of Montreal, Montreal, QC H2W 1R7, Canada.ORCID 0000-0002-2283-7632
Nabil G SeidahLaboratory of Biochemical Neuroendocrinology, Montreal Clinical Research Institute (IRCM), affiliated to the University of Montreal, Montreal, QC H2W 1R7, Canada.ORCID 0000-0001-6503-9342

Funding

CIHR 148363CIHR 191678CIHR 950-231335
6 · The paper itself

Abstract

From a previously performed proteomics screen, GPP130, or Golgi phosphoprotein of 130 kDa, was identified as a potential substrate of the proprotein convertase 7 (PC7; PCSK7). GPP130 is a type-II transmembrane protein with a luminal domain containing endosomal and Golgi-retrieval determinants, enabling a unique trafficking route. Most of the previous work on GPP130 relates to its binding and retrograde trafficking of the Shiga toxin. However, its cellular biology and its biochemical characterization remain understudied. Recently, GPP130 was reported to be implicated in cell cycle progression and cell proliferation in head and neck cancer cells. This led us to analyze the cBioPortal for Cancer Genomics, revealing that the GPP130/GOLIM4 gene is amplified in many cancers, including lung, ovarian, and cervical. This observation led us to use the A549 lung cancer cell line to investigate the growth-regulating roles of endogenous and overexpressed GPP130 and to analyze the impact of its cleavage/shedding by PC7 and/or Furin on cellular growth. Our cell-based assays suggest that GPP130 is a novel pro-protein convertase substrate that increases cell proliferation in A549, SKOV3, and HeLa cells, and that the latter activity is enhanced following its cleavage by PC7 and/or Furin into a membrane-bound N-terminal product and secreted C-terminal fragments. This novel work sheds light on the cell biology of the poorly characterized GPP130, its proliferative activity, and modulation upon its shedding by PC7 and Furin in lung cancer progression.

Indexed as

FurinLung NeoplasmsMembrane ProteinsSubtilisinsA549 CellsCell Line, TumorCell ProliferationDisease ProgressionHeLa CellsHumansFurinFURIN protein, humanMembrane ProteinsPCSK7 protein, humanSubtilisinsCys-palmitoylationfurinGOLIM4 proprotein convertasesGPP130lung cancerPC7post-translational modificationsproteolysis

Identifiers

PMID40649939
PMCPMC12250082

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.